Payden & Rygel’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-292,800
| Closed | -$17.9M | – | 115 |
|
|
2025
Q1 | $17.9M | Buy |
292,800
+45,000
| +18% | +$2.62M | 1.53% | 25 |
|
|
2024
Q4 | $14M | Buy |
+247,800
| New | +$13.8M | 1.21% | 41 |
|
|
2024
Q2 | – | Sell |
-3,800
| Closed | -$206K | – | 125 |
|
|
2024
Q1 | $206K | Hold |
3,800
| – | – | 0.01% | 117 |
|
|
2023
Q4 | $195K | Hold |
3,800
| – | – | 0.01% | 124 |
|
|
2023
Q3 | $221K | Hold |
3,800
| – | – | 0.02% | 118 |
|
|
2023
Q2 | $243K | Sell |
3,800
-203,940
| -98% | -$13.7M | 0.02% | 115 |
|
|
2023
Q1 | $14.4M | Sell |
207,740
-235,320
| -53% | -$16.6M | 0.85% | 58 |
|
|
2022
Q4 | $31.9M | Sell |
443,060
-4,200
| -0.9% | -$317K | 1.7% | 18 |
|
|
2022
Q3 | $31.8M | Buy |
447,260
+77,800
| +21% | +$5.64M | 1.86% | 13 |
|
|
2022
Q2 | $28.4M | Hold |
369,460
| – | – | 1.71% | 16 |
|
|
2022
Q1 | $27M | Sell |
369,460
-352,500
| -49% | -$23.7M | 1.36% | 29 |
|
|
2021
Q4 | $45M | Buy |
721,960
+5,800
| +0.8% | +$340K | 2.08% | 5 |
|
|
2021
Q3 | $42.4M | Buy |
716,160
+371,460
| +108% | +$24.5M | 2.2% | 6 |
|
|
2021
Q2 | $23M | Sell |
344,700
-123,600
| -26% | -$8.06M | 1.1% | 50 |
|
|
2021
Q1 | $29.6M | Buy |
468,300
+9,300
| +2% | +$579K | 1.37% | 33 |
|
|
2020
Q4 | $28.5M | Sell |
459,000
-6,400
| -1% | -$394K | 1.46% | 33 |
|
|
2020
Q3 | $28.1M | Sell |
465,400
-102,000
| -18% | -$6.14M | 1.66% | 25 |
|
|
2020
Q2 | $33.4M | Sell |
567,400
-7,100
| -1% | -$425K | 2.13% | 10 |
|
|
2020
Q1 | $32M | Buy |
574,500
+40,508
| +8% | +$2.48M | 2.31% | 13 |
|
|
2019
Q4 | $34.3M | Buy |
533,992
+217,000
| +68% | +$12.4M | 2.14% | 15 |
|
|
2019
Q3 | $16.1M | Buy |
+316,992
| New | +$14.9M | 1.09% | 44 |
|
|
2015
Q3 | – | Sell |
-240
| Closed | -$16K | – | 128 |
|
|
2015
Q2 | $16K | Hold |
240
| – | – | ﹤0.01% | 153 |
|
|
2015
Q1 | $15K | Hold |
240
| – | – | ﹤0.01% | 169 |
|
|
2014
Q4 | $14K | Hold |
240
| – | – | ﹤0.01% | 170 |
|
|
2014
Q3 | $12K | Hold |
240
| – | – | ﹤0.01% | 178 |
|
|
2014
Q2 | $12K | Hold |
240
| – | – | ﹤0.01% | 191 |
|
|
2014
Q1 | $12K | Buy |
240
+140
| +140% | +$7.45K | ﹤0.01% | 185 |
|
|
2013
Q4 | $5K | Hold |
100
| – | – | ﹤0.01% | 211 |
|
|
2013
Q3 | $5K | Hold |
100
| – | – | ﹤0.01% | 194 |
|
|
2013
Q2 | $4K | Buy |
+100
| New | +$4.34K | ﹤0.01% | 207 |
|
Other funds holding BMY
Payden & Rygel's BMY Position: Q2 2025 in Review
Payden & Rygel sold out of Bristol-Myers Squibb (BMY) in Q2 2025, closing a stake of 292,800 shares — an estimated $17.9M sold.
Payden & Rygel first reported a position in BMY in Q2 2013 and held it in 30 quarters. The position peaked at $45M in Q4 2021. 2,292 funds tracked by Wall St. Rank hold BMY as of Q2 2025.
- Payden & Rygel reported no remaining Bristol-Myers Squibb position as of Q2 2025 after selling out during the quarter.
- Payden & Rygel sold 292,800 Bristol-Myers Squibb shares in Q2 2025, an estimated $17.9M.
- Payden & Rygel first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 30 quarters.
- Payden & Rygel's Bristol-Myers Squibb position peaked at $45M in Q4 2021.
- 2,292 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2025.
Based on Payden & Rygel's 13F filing for Q2 2025, filed 7 Aug 2025.